• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma: an open-label, multicenter, phase 1 study (MMY1010)

by | Jun 4, 2024 | Publications

Blood Sci. 2024 May 31;6(3):e00193. doi: 10.1097/BS9.0000000000000193. eCollection 2024 Jul. ABSTRACT Despite recent progress in multiple myeloma (MM) treatments, most patients will relapse and require additional treatment. Intravenous daratumumab, a human IgGκ...

CD8(+) CD28(-) regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study

by | Jun 4, 2024 | Publications

Leukemia. 2024 Jun 3. doi: 10.1038/s41375-024-02290-y. Online ahead of print. NO ABSTRACT PMID:38830959 | DOI:10.1038/s41375-024-02290-y

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

by | Jun 4, 2024 | Publications

Nat Med. 2024 Jun 3. doi: 10.1038/s41591-024-03050-2. Online ahead of print. ABSTRACT CD38-targeting immunotherapy is approved in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) that are transplant ineligible...

Identification and evaluation of a six-lncRNA prognostic signature for multiple myeloma

by | Jun 4, 2024 | Publications

Discov Oncol. 2024 Jun 3;15(1):204. doi: 10.1007/s12672-024-01064-3. ABSTRACT PURPOSE: Multiple myeloma (MM) is the second most common hematologic malignancy, and there is no cure for this disease. This study aimed to explore the prognostic value of long noncoding...

Inference of genomic lesions from single-cell RNAseq in myeloma improves functional intra- and inter-clonal analysis

by | Jun 3, 2024 | Publications

Blood Adv. 2024 Jun 3:bloodadvances.2023012409. doi: 10.1182/bloodadvances.2023012409. Online ahead of print. ABSTRACT Smoldering Multiple Myeloma (SMM) is an asymptomatic plasma cell (PC) neoplasm that may evolve with variable frequency into multiple myeloma (MM)....

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

by | Jun 3, 2024 | Publications

N Engl J Med. 2024 Jun 1. doi: 10.1056/NEJMoa2405090. Online ahead of print. ABSTRACT BACKGROUND: Belantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent in...
« Older Entries
Next Entries »

Recent Content

  • (no title)
  • Caribou’s CB-011 may be effective, safe for hard-to-treat myeloma
  • Therapy wins rare pediatric disease designation for hard-to-treat glioma
  • November shines a spotlight on pancreatic cancer awareness
  • Cero seeking more safety, dosing data on T-cell therapy for AML
  • (no title)
  • Efficacy of novel therapies for refractory and relapsed multiple myeloma in China: A scoping systematic review
  • Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
  • Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT